CGEM
HEALTHCARECullinan Oncology Inc
$14.99+0.05 (+0.33%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving CGEM Today?
No stock-specific AI insight has been generated for CGEM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.68$16.74
$14.99
Fundamentals
Market Cap$921M
P/E Ratio—
EPS$-3.36
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume886K
Avg Volume (10D)—
Shares Outstanding61.5M
CGEM News
20 articles- Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsYahoo Finance·Apr 28, 2026
- Will Health Benefits Weakness Drag Elevance's Q1 Earnings?Yahoo Finance·Apr 16, 2026
- Cullinan Therapeutics flags 2026 as “defining year” at Leerink, tees up key CLN-978/CLN-049 dataMarketbeat·Mar 14, 2026
- CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsightYahoo Finance·Mar 10, 2026
- Cullinan Therapeutics: Q4 Earnings SnapshotYahoo Finance·Mar 10, 2026
- Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsYahoo Finance·Mar 10, 2026
- Cullinan Therapeutics Maps 2026 Data Catalysts for Autoimmune CLN-978, AML CLN-049 at TD Cowen ConferenceMarketbeat·Mar 8, 2026
- Cullinan Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·Feb 24, 2026
- Cullinan Therapeutics Touts 2026 “Defining Year” as T-Cell Engager, Zipalertinib Catalysts NearMarketbeat·Feb 20, 2026
- TheStreet Pro Analysts Say, “It’s a Stock Picker’s Market – Here Are 4 to Consider”Yahoo Finance·Feb 19, 2026
- Cullinan Therapeutics Tees Up Catalyst-Heavy 2026 With Q2 CLN-978 Data and AML Fast Track MomentumMarketbeat·Feb 13, 2026
- Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026Yahoo Finance·Feb 5, 2026
- Here's What Could Help Cullinan Therapeutics (CGEM) Maintain Its Recent Price StrengthYahoo Finance·Jan 23, 2026
- [Latest] Global T-Cell Engagers Market Size/Share Worth USD 18.8 Billion by 2034 at a 21.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)Yahoo Finance·Jan 14, 2026
- Adimab Reports Strong Partnering Year for 2025Yahoo Finance·Jan 12, 2026
- Cullinan Therapeutics provides corporate update, anticipated 2026 milestonesYahoo Finance·Jan 9, 2026
- Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 MilestonesYahoo Finance·Jan 8, 2026
- Will Cullinan Therapeutics (NASDAQ:CGEM) Spend Its Cash Wisely?Yahoo Finance·Dec 17, 2025
- Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response RatesYahoo Finance·Dec 16, 2025
All 20 articles loaded
Price Data
Open$15.48
Previous Close$14.94
Day High$15.75
Day Low$14.21
52 Week High$16.74
52 Week Low$5.68
52-Week Range
$5.68$16.74
$14.99
Fundamentals
Market Cap$921M
P/E Ratio—
EPS$-3.36
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin—
Debt / Equity—
Trading
Volume886K
Avg Volume (10D)—
Shares Outstanding61.5M
About Cullinan Oncology Inc
Cullinan Management, Inc., a biopharmaceutical company, is focused on developing a line of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—